JP2014502150A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502150A5
JP2014502150A5 JP2013538846A JP2013538846A JP2014502150A5 JP 2014502150 A5 JP2014502150 A5 JP 2014502150A5 JP 2013538846 A JP2013538846 A JP 2013538846A JP 2013538846 A JP2013538846 A JP 2013538846A JP 2014502150 A5 JP2014502150 A5 JP 2014502150A5
Authority
JP
Japan
Prior art keywords
seq
antibody
hvr
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538846A
Other languages
English (en)
Japanese (ja)
Other versions
JP6163429B2 (ja
JP2014502150A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059964 external-priority patent/WO2012064836A1/en
Publication of JP2014502150A publication Critical patent/JP2014502150A/ja
Publication of JP2014502150A5 publication Critical patent/JP2014502150A5/ja
Application granted granted Critical
Publication of JP6163429B2 publication Critical patent/JP6163429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538846A 2010-11-10 2011-11-09 神経疾患免疫治療のための方法及び組成物 Active JP6163429B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45664210P 2010-11-10 2010-11-10
US61/456,642 2010-11-10
US41831010P 2010-11-30 2010-11-30
US61/418,310 2010-11-30
US41885010P 2010-12-01 2010-12-01
US61/418,850 2010-12-01
US201061426425P 2010-12-22 2010-12-22
US61/426,425 2010-12-22
PCT/US2011/059964 WO2012064836A1 (en) 2010-11-10 2011-11-09 Methods and compositions for neural disease immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017018384A Division JP2017137312A (ja) 2010-11-10 2017-02-03 神経疾患免疫治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2014502150A JP2014502150A (ja) 2014-01-30
JP2014502150A5 true JP2014502150A5 (enExample) 2014-12-25
JP6163429B2 JP6163429B2 (ja) 2017-07-12

Family

ID=45002151

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538846A Active JP6163429B2 (ja) 2010-11-10 2011-11-09 神経疾患免疫治療のための方法及び組成物
JP2017018384A Pending JP2017137312A (ja) 2010-11-10 2017-02-03 神経疾患免疫治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017018384A Pending JP2017137312A (ja) 2010-11-10 2017-02-03 神経疾患免疫治療のための方法及び組成物

Country Status (22)

Country Link
US (3) US8772457B2 (enExample)
EP (2) EP2638070B1 (enExample)
JP (2) JP6163429B2 (enExample)
KR (1) KR20130133205A (enExample)
CN (1) CN103228674B (enExample)
AR (1) AR083819A1 (enExample)
AU (1) AU2011326564A1 (enExample)
CA (1) CA2815840A1 (enExample)
CL (1) CL2013001290A1 (enExample)
CO (1) CO6690815A2 (enExample)
EA (1) EA201390669A1 (enExample)
EC (1) ECSP13012673A (enExample)
ES (1) ES2607086T3 (enExample)
IL (1) IL226106A0 (enExample)
MA (1) MA34722B1 (enExample)
MX (1) MX346500B (enExample)
PE (1) PE20140238A1 (enExample)
PH (1) PH12013500933A1 (enExample)
SG (1) SG190682A1 (enExample)
TW (1) TW201300417A (enExample)
WO (1) WO2012064836A1 (enExample)
ZA (1) ZA201302980B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772457B2 (en) 2010-11-10 2014-07-08 Genentech, Inc. BACE1 antibodies
CN103852579B (zh) * 2012-12-05 2018-02-23 姚钧 一种人体血清Aβ的定量检测方法
US10640549B2 (en) 2014-10-17 2020-05-05 University Of Virginia Patent Foundation Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
JP6859259B2 (ja) * 2014-11-19 2021-04-14 ジェネンテック, インコーポレイテッド BACElに対する抗体及び神経疾患免疫療法のためのその使用
EP3101424B1 (en) * 2015-06-04 2023-01-04 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
EP3325506A1 (en) * 2015-07-21 2018-05-30 BioArctic AB Method for treatment of traumatic brain injury targeting aggregated peptides
WO2017158064A1 (en) * 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
CN106084057A (zh) * 2016-06-13 2016-11-09 东北师范大学 Bace1剪切型高效价抗体的制备及应用
CN107475260B (zh) * 2017-09-08 2020-12-04 东北师范大学 抑制大脑中Aβ累积的BACE1亚型的功能研发及应用
CN107523579A (zh) * 2017-09-08 2017-12-29 东北师范大学 促进大脑中Aβ累积的BACE1亚型的功能研发及应用
JP6873445B2 (ja) 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−9抗体及びその使用
WO2019094608A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
US12350278B2 (en) 2018-06-27 2025-07-08 Joshua O. Atiba Therapy and prevention of prion protein complex infections in non-human animals
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
US20220178930A1 (en) * 2019-05-01 2022-06-09 New York University Anti-galectin-9 antibodies and uses thereof
EP4551600A1 (en) 2022-07-04 2025-05-14 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5200339A (en) 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
WO1992003542A1 (en) 1990-08-17 1992-03-05 Boston University PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID β-PROTEIN PRECURSOR
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6329163B1 (en) 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998026059A1 (en) 1996-12-11 1998-06-18 Athena Neurosciences, Inc. Beta-secretase isolated from human 293 cells
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
NZ534876A (en) 1999-02-10 2006-02-24 Elan Pharm Inc Human beta-secretase enzyme, inhibitors and their compositions and uses
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
CA2410898A1 (en) 2000-07-19 2002-01-24 Pharmacia & Upjohn Company Substrates and assays for .beta.-secretase activity
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
DE60126970T2 (de) * 2000-09-22 2007-11-22 Wyeth Kristallstruktur von bace und verwendungen dafür
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020157122A1 (en) * 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
WO2002053594A2 (en) 2000-12-28 2002-07-11 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
EP1395275B1 (en) 2001-05-22 2008-11-12 Merck & Co., Inc. Beta-secretase substrate and uses thereof
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk MODIFIED GENOME CELLS
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 FcγRIIIa多型患者に適応する抗体組成物含有医薬
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
EP2305710A3 (en) * 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003285892A1 (en) 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP4739192B2 (ja) 2003-05-02 2011-08-03 イーラン ファーマスーティカルズ、インコーポレイテッド Baceのグリコシル化変異体
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005014815A1 (en) 2003-08-08 2005-02-17 President And Fellows Of Harvard College siRNA BASED METHODS FOR TREATING ALZHEIMER’S DISEASE
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
US20070149763A1 (en) 2003-10-15 2007-06-28 Bristol-Myers Squibb Company Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
WO2005045021A1 (en) * 2003-11-06 2005-05-19 Exonhit Therapeutics Sa Bace455, an alternative splice variant of the human beta-secretase
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005049802A2 (en) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP4778906B2 (ja) 2004-10-01 2011-09-21 武田薬品工業株式会社 膜貫通型酵素阻害物質のスクリーニング方法
RU2418004C2 (ru) * 2004-10-04 2011-05-10 Дженентек, Инк. Модуляторы активатора фактора роста гепатоцитов
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2618508A1 (en) 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
RU2450020C2 (ru) * 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ZA200806187B (en) * 2006-01-20 2009-10-28 Genentech Inc Anti-EphrinB2 antibodies and methods using same
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
PE20081760A1 (es) * 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
EP2139496A2 (en) 2007-04-19 2010-01-06 Vib Vzw Oligonucleotide compositions for the treatment of alzheimer's disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2281005B1 (en) * 2008-04-03 2013-11-20 Vib Vzw Single domain antibodies capable of modulating bace1 activity
US7989597B2 (en) 2008-06-20 2011-08-02 Oklahoma Medical Research Foundation Immunogenic memapsin 2 β-secretase peptides and methods of use
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
US20100233156A1 (en) 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
JP5944822B2 (ja) 2009-06-15 2016-07-05 フエー・イー・ベー・フエー・ゼツト・ウエー Bace1抑制性抗体
US8772457B2 (en) 2010-11-10 2014-07-08 Genentech, Inc. BACE1 antibodies
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
AU2012244816B2 (en) 2011-04-20 2015-12-10 Roche Glycart Ag Method and constructs for the pH dependent passage of the blood-brain-barrier
US20150353639A1 (en) 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport

Similar Documents

Publication Publication Date Title
JP2014502150A5 (enExample)
JP7595061B2 (ja) 抗タウ抗体およびその使用
CN110799531B (zh) 抗PHF-tau抗体及其用途
JP2018505651A5 (enExample)
JP7109467B2 (ja) タウに特異的に結合する結合分子
CN112105639B (zh) 抗PHF-tau抗体及其用途
JP2022500081A (ja) 抗trem−2アゴニスト抗体
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
US12116407B2 (en) Methods of treating neurodegenerative diseases
RU2014108309A (ru) Антиполиубиквитиновые антитела и способы применения
CN116348487A (zh) 抗淀粉样β抗体
KR20240139072A (ko) 신경 변성 질환의 치료제
JPWO2021010712A5 (enExample)
CN111518207B (zh) 人源化抗Aβ单克隆抗体及其应用
JP2022528459A (ja) 融合構築物及びその使用
CN120858110A (zh) 用抗Aβ抗体治疗神经病症的方法
EP3990488A1 (en) Semaphorin 3a antibodies and uses thereof
US12509512B2 (en) Semaphorin 3A antibodies and uses thereof
HK40042273A (en) Anti-phf-tau antibodies and uses thereof
EA045151B1 (ru) Антитела анти-phf-тау и их применение